VCYT - Veracyte Inc
IEX Last Trade
31.56
-0.380 -1.204%
Share volume: 676,769
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$31.94
-0.38
-1.19%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-03 | 2022-11-03 | 2023-03-01 | 2023-05-05 | 2023-08-09 | 2023-11-08 | 2024-02-29 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 1.144 B | 1.126 B | 1.156 B | 1.157 B | 1.161 B | 1.125 B | 1.115 B | 1.200 B | |
| Current Assets | 235.045 M | 238.516 M | 248.636 M | 251.503 M | 259.480 M | 271.163 M | 285.621 M | 290.418 M | |
| Inventories | 14.600 M | 13.798 M | 14.294 M | 13.306 M | 11.572 M | 15.887 M | 16.128 M | 18.328 M | |
| Other Current Assets | 15.999 M | 14.538 M | 11.469 M | 14.818 M | 14.401 M | 13.516 M | 12.661 M | 16.237 M | |
| Short Term Investments | 15.999 M | 14.538 M | 11.469 M | 14.818 M | 14.401 M | 13.516 M | 12.661 M | 16.237 M | |
| Total Receivables | 40.448 M | 40.068 M | 44.021 M | 45.489 M | 42.365 M | 39.297 M | 40.378 M | 46.665 M | |
| Current Cash | 163.998 M | 170.112 M | 178.852 M | 177.890 M | 191.142 M | 202.463 M | 216.454 M | 209.188 M | |
| Total Non-current Assets | 909.153 M | 887.441 M | 907.786 M | 905.616 M | 901.634 M | 853.780 M | 829.285 M | 909.655 M | |
| Property Plant Equipment | 17.188 M | 17.237 M | 17.702 M | 18.072 M | 18.510 M | 19.288 M | 20.584 M | 21.566 M | |
| Other Assets | 16.809 M | 16.028 M | 18.578 M | 16.851 M | 18.571 M | 16.879 M | 16.248 M | 16.806 M | |
| Intangible Assets | 184.367 M | 176.542 M | 174.866 M | 170.226 M | 164.744 M | 123.567 M | 88.593 M | 116.348 M | |
| Goodwill | 690.040 M | 676.885 M | 695.891 M | 699.718 M | 698.920 M | 693.176 M | 702.984 M | 753.853 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.144 B | 1.126 B | 1.156 B | 1.157 B | 1.161 B | 1.125 B | 1.115 B | 1.200 B | |
| Total liabilities | 80.047 M | 77.780 M | 81.222 M | 75.860 M | 78.396 M | 70.884 M | 70.804 M | 81.424 M | |
| Total current liabilities | 59.345 M | 58.352 M | 62.614 M | 55.993 M | 58.151 M | 57.260 M | 61.241 M | 58.052 M | |
| Accounts Payable | 10.328 M | 11.114 M | 11.911 M | 15.655 M | 12.895 M | 12.531 M | 12.943 M | 12.152 M | |
| Other liabilities | 3.568 M | 3.559 M | 3.429 M | 5.564 M | 5.647 M | 1.260 M | 1.304 M | 13.974 M | |
| Current long term debt | 5.063 M | 5.145 M | 4.070 M | 4.076 M | 4.973 M | 5.007 M | 5.105 M | 5.982 M | |
| Long term debt | 12.529 M | 11.527 M | 10.648 M | 9.709 M | 9.891 M | 8.720 M | 7.525 M | 8.058 M | |
| Other liabilities | 3.568 M | 3.559 M | 3.429 M | 5.564 M | 5.647 M | 1.260 M | 1.304 M | 13.974 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.064 B | 1.048 B | 1.075 B | 1.081 B | 1.083 B | 1.054 B | 1.044 B | 1.119 B | |
| Common stock | 71.477 M | 71.657 M | 71.833 M | 72.175 M | 72.479 M | 72.805 M | 73.119 M | 74.760 M | |
| Retained earnings | -381.150 M | -389.873 M | -393.717 M | -401.808 M | -410.210 M | -439.828 M | -468.121 M | -469.985 M |